Royalty Pharma Plc Earnings

Royalty Pharma Plc’s revenue jumped 0.05% since last year same period to $568.25Mn in the Q1 2025. On a quarterly growth basis, Royalty Pharma Plc has generated -4.34% fall in its revenue since last 3-months.

Royalty Pharma Plc’s net profit jumped 4888.47% since last year same period to $238.35Mn in the Q1 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 14.59% jump in its net profits since last 3-months.

Royalty Pharma Plc’s net profit margin jumped 4886.11% since last year same period to 41.94% in the Q1 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 19.78% jump in its net profit margins since last 3-months.

Royalty Pharma Plc’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.55.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 1.05 - a 0.96% jump from last quarter’s estimates.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 1.05.

Royalty Pharma Plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Royalty Pharma Plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.